IN THE CLAIMS

1. (Currently Amended) ~~Vaccine~~ A vaccine adjuvant ~~adjuvants~~ characterized by a Proteoliposomic structure or a ~~derivatives~~ derivative thereof having the capability ~~of it capable~~ to induce a CTL response.

2. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 1, characterized by a bacterial origin.

3. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 2, ~~that come from~~ comprising a Neisseria or Salmonella genus.

4. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 1, which ~~express~~ expresses ~~the antigens~~ at least one antigen of interest from a strain modified by genetic ~~engeneering~~ engineering.

5. (Currently Amended) ~~Vaccine~~ A vaccine formulation comprising the adjuvant ~~characterized by including the adjuvants described from~~ of claim 1 ~~to 4~~, further comprising at least one ~~or more antigens~~ antigen of interest ~~as well as suitable~~ and an excipient.

6. (Currently Amended) ~~Vaccine~~ The vaccine formulation of ~~like in~~ claim 5, characterized by the insertion of the antigen ~~(s)~~ of interest in the lipidic bilayer of the Proteoliposomes or a derivative thereof ~~being also present in its derivatives~~.

7. (Currently Amended) ~~Vaccine~~ The vaccine formulation ~~like in~~of claim 5, characterized by the conjugation of the antigen ~~(s)~~ of interest to the Proteoliposomes or a derivative thereof ~~being also present in its derivatives~~.

8. (Currently Amended) The vaccine ~~Vaccine~~ formulation of ~~like in~~ claim 5, characterized by ~~the~~a co-administration of the antigen ~~(s)~~ of interest with the Proteoliposomes or ~~its derivatives~~ derivative thereof.

9. (Currently Amended) The vaccine ~~Vaccine~~ formulation ~~like in~~ of claim 5, characterized by a concentration ~~rank~~ of the Proteoliposomes or ~~its derivatives~~ a derivative thereof between 1 and 50 µg~~, particularly between 5 and 25 µg~~.

10. (Currently Amended) The vaccine ~~Vaccine~~ formulation ~~like in~~ of claim 5, characterized by a concentration ~~rank~~ of the antigen ~~(s)~~ of interest from 0.1 to 20% of the mass of the Proteoliposomes or ~~its derivatives~~ a derivative thereof~~, particularly from 0.5 to 10%~~.

11. (Currently Amended) The vaccine ~~Vaccine~~ formulation of ~~like in claims~~ claim 5 ~~to 10~~, ~~which~~ said formulation being in a form to be administered by at least one of the following means, intramuscularly, intraperitonealy, intradermicaly, subcutaneously, ~~or~~ mucosaly by oral/feed, ~~or~~ nasal/respiratory routes and ~~or by~~ genitourinary tract.

12. (Currently Amended) The use of vaccine formulation like ~~in claims 5 to~~ of claim 10, comprising administering the formulation to a mammal in need of treatment to protect said mammal ~~mammalians~~ susceptible to infections or ~~and~~ to treat tumoral ~~deseases~~ diseases.

13. (Currently Amended) An immunization ~~Immunization~~ schedule comprising administering ~~using~~ the vaccine formulation ~~like in claims~~ of claim 5 ~~to 10~~, characterized by ~~the application~~ administering ~~of~~ three doses of said formulation as a maximum to achieve a ~~profilactic~~ prophylactic ~~effect and five doses as maximum to achieve a therapeutic~~ effect.

14. (New) An immunization schedule comprising administering the formulation of claim 10, and further characterized by administering 5 doses of said formulation as a maximum to achieve a therapeutic effect.

15. (New) The vaccine formulation of claim 9, wherein the concentration is between 5 and 25 µg.

16. (New) The vaccine formulation of claim 10, wherein the concentration is between 0.5 to 10% of said mass.

17. (New) A method for treating a mammal for tumoral diseases comprising:

(a) providing a formulation comprising a vaccine adjuvant comprising a Proteoliposomes structure or a derivative thereof.

(b) administering the formulation of step (a) to a mammal in need of said treatment.

18. (New) The method of claim 17, wherein the formulation comprises at least one antigen of interest, and wherein the concentration of the antigen of interest is from 0.1 to 20% by weight of the mass of the Proteoliposomes or in a derivative thereof.